Today’s Stock Alert: Eli Lilly and Co Declines Again; Strong Momentum for Sellers

Today's Stock Alert: Eli Lilly and Co Declines Again; Strong Momentum for Sellers

The stock of Eli Lilly and Co (NYSE:LLY) is a huge mover today! The stock decreased 10.51% or $7.99 on November 23, hitting $68. About 53.98M shares traded hands or 1167.14% up from the average. Eli Lilly and Co (NYSE:LLY) has declined 12.63% since April 22, 2016 and is downtrending. It has underperformed by 18.04% the S&P500.
The move comes after 5 months negative chart setup for the $74.43 billion company. It was reported on Nov, 24 by Barchart.com. We have $61.88 PT which if reached, will make NYSE:LLY worth $6.70B less.

Analysts await Eli Lilly and Co (NYSE:LLY) to report earnings on January, 31 before the open. They expect $0.99 EPS, up 26.92% or $0.21 from last year’s $0.78 per share. LLY’s profit will be $1.08 billion for 17.17 P/E if the $0.99 EPS becomes a reality. After $0.88 actual EPS reported by Eli Lilly and Co for the previous quarter, Wall Street now forecasts 12.50% EPS growth.

Eli Lilly and Co (NYSE:LLY) Ratings Coverage

Out of 15 analysts covering Eli Lilly and Company (NYSE:LLY), 14 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 93% are positive. $125 is the highest target while $75 is the lowest. The $97.88 average target is 43.94% above today’s ($68) stock price. Eli Lilly and Company has been the topic of 40 analyst reports since July 23, 2015 according to StockzIntelligence Inc. The stock of Eli Lilly and Co (NYSE:LLY) has “Buy” rating given on Friday, September 18 by Jefferies. Atlantic Securities initiated the stock with “Overweight” rating in Friday, December 18 report. Argus Research maintained it with “Buy” rating and $95 target price in Tuesday, August 2 report. As per Thursday, September 8, the company rating was upgraded by JP Morgan. The firm has “Buy” rating given on Monday, December 7 by Deutsche Bank. The stock of Eli Lilly and Co (NYSE:LLY) earned “Buy” rating by Bank of America on Friday, September 18. Leerink Swann maintained it with “Outperform” rating and $101 target price in Monday, May 2 report. Jefferies maintained the stock with “Buy” rating in Tuesday, March 15 report. The stock of Eli Lilly and Co (NYSE:LLY) earned “Outperform” rating by Cowen & Co on Saturday, August 22. As per Thursday, July 14, the company rating was maintained by Jefferies.

According to Zacks Investment Research, “Eli Lilly and Company discovers, develops, manufactures, and sells products in one significant business segment -pharmaceutical products. The company directs its research efforts primarily toward the search for products to diagnose, prevent and treat human diseases. The company also conducts research to find products to treat diseases in animals and to increase the efficiency of animal food production.”

Insitutional Activity: The institutional sentiment increased to 1.08 in Q2 2016. Its up 0.01, from 1.07 in 2016Q1. The ratio increased, as 54 funds sold all Eli Lilly and Co shares owned while 365 reduced positions. 88 funds bought stakes while 362 increased positions. They now own 814.98 million shares or 2.31% less from 834.25 million shares in 2016Q1.
Blackrock Institutional Tru Na holds 26.67M shares or 0.34% of its portfolio. Tcw Gru owns 78,150 shares or 0.05% of their US portfolio. 1St Global Advsr has 28,543 shares for 0.31% of their US portfolio. Dreman Value L L C accumulated 0.04% or 900 shares. Natl Ins Tx owns 178,370 shares or 0.82% of their US portfolio. Texan Capital reported 30,437 shares or 1.1% of all its holdings. Nuveen Asset Limited Company has invested 0.04% of its portfolio in Eli Lilly and Co (NYSE:LLY). The Indiana-based Lynch & Associates In has invested 0.25% in Eli Lilly and Co (NYSE:LLY). Accredited Invsts Incorporated owns 3,225 shares or 0.07% of their US portfolio. Douglass Winthrop Advisors Ltd Liability Corporation accumulated 3,000 shares or 0.02% of the stock. Principal Fincl Gru accumulated 1.43M shares or 0.16% of the stock. Ameriprise Financial accumulated 835,387 shares or 0.04% of the stock. Nj State Employees Deferred Compensation Plan has 35,000 shares for 0.59% of their US portfolio. Vident Inv Advisory Limited Liability reported 8,704 shares or 0.1% of all its holdings. First City Cap owns 23,973 shares or 1.43% of their US portfolio.

Insider Transactions: Since May 31, 2016, the stock had 1 buy, and 10 selling transactions for $120.57 million net activity. On Tuesday, July 12 the insider LILLY ENDOWMENT INC sold $16.70 million. On Tuesday, October 4 Crowe Maria A sold $182,927 worth of the stock or 2,248 shares. $205,875 worth of shares were bought by TAI JACKSON P on Friday, August 12. Zakrowski Donald A sold 1,213 shares worth $100,873. $73,180 worth of Eli Lilly and Co (NYSE:LLY) shares were sold by Barnes Melissa S.

More notable recent Eli Lilly and Co (NYSE:LLY) news were published by: Marketwatch.com which released: “Eli Lilly shares slide premarket after company says Alzheimer’s drug trial failed” on November 23, 2016, also Forbes.com with their article: “January 2017 Options Now Available For Eli Lilly (LLY)” published on November 23, 2016, Bloomberg.com published: “Eli Lilly’s Diabetes Misery Will Have Company” on October 26, 2016. More interesting news about Eli Lilly and Co (NYSE:LLY) were released by: Fool.com and their article: “Better Buy: Eli Lilly and Co vs. Pfizer” published on October 26, 2016 as well as Schaeffersresearch.com‘s news article titled: “Buzz Stocks: Juno Therapeutics Inc, Eli Lilly and Co, and Biogen Inc” with publication date: November 23, 2016.

LLY Company Profile

Eli Lilly and Company, incorporated on January 17, 1901, is engaged in drug manufacturing business. The Firm discovers, develops, makes and markets products in two divisions: human pharmaceutical products and animal health products. The Company’s products are sold in over 120 countries. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists. The Company’s animal health business segment operates through the Company’s Elanco division, which develops, makes and markets products for both food animals and companion animals. The Firm makes and distributes its products through facilities in the United States, Puerto Rico and over 10 other countries.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment